Real-time three-dimensional echocardiography (RT3DE) evaluation of the right ventricle (RV) decreases geometric assumptions from conventional echocardiography. RV strain has been demonstrated to be more sensitive in evaluation of RV function than conventional echocardiography. TomTec 4D RV-Function 2 software is vendor neutral and can generate RV size and functional parameters. We compared 4D RV-Function 2 data between controls and pediatric pulmonary hypertension (PH) patients. We also compared tricuspid annular plane excursion (TAPSE) and fractional area change (FAC) measured by 4D RV-Function 2 and by traditional two-dimensional echocardiography. We enrolled 145 children with PH with 161 visits (mean age: 11.5 ± 6.9 years; 47% male) and 13 controls (mean age: 8.6 ± 2.5 years; 66% male) who underwent RT3DE evaluation of the RV in 2014-2015. Offline analysis of the 4D RV-Function 2 data of these patients generated RV indices: 3D ejection fraction (EF), RV septal and free-wall longitudinal strain (RVLS), TAPSE, and FAC. Differences in RV indices between PH patients and controls were assessed with linear mixed models, adjusting for age and accounting for repeated measures. A t test was performed on the TAPSE and FAC from traditional two-dimensional echocardiography and compared to the TAPSE and FAC generated from the 4D RV-Function 2 software in pediatric PH patients. TAPSE is measured in 4D RV-Function 2 by taking the difference between the length from the apex to the tricuspid valve annulus in systole and that in diastole. Intraclass correlations (ICCs) between two users were tested. There were significant differences in RV indices between PH patients and controls, with the exception of TAPSE. There were also significant differences in TAPSE and FAC between the two-dimensional echocardiography and 4D RV-Function 2. The ICCs showed good agreement for EF and RV free-wall longitudinal strain (0.92 and 0.82, respectively). The ICCs showed moderate agreement in RV septal longitudinal strain, TASPE, and FAC (0.62, 0.66, and 0.64, respectively). Pediatric PH patients have impaired RV function compared to normal children. The 4D RV-Function 2 software is feasible and generates RV functional parameters from one RT3DE acquisition, making it easier for clinical use. Differences between the values of TAPSE and FAC from the two methods will need to be evaluated further to define the normal values gen-Pulm Circ 2016;6(3):389-396. DOI: 10.1086/687256. erated from 4D RV-Function 2, as this method measures TAPSE differently than the traditional M-mode measurement of TAPSE.
Bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) is a prominent source of morbidity and mortality in the premature infant population. Both hypoxia and hyperoxia have been implicated as potential contributors to the pathogenesis of BPD-PH. The optimal oxygen saturation target range to minimize risk for BPD-PH is in dispute. A large, single-center neonatal intensive care unit has changed its pulse oximetry targets twice in the past 7 years for reasons unrelated to PH risk. We hypothesized that exposure to increased pulse oximetry targets would result in lower rates of BPD-PH. We retrospectively compared rates of PH and use of PH medications (sildenafil, inhaled nitric oxide [iNO] , and bosentan) in at-risk infants exposed to varying saturation targets. Infants with birth weight of <1,500 grams and gestational age of 23-32 weeks were divided into 3 cohorts: group 1, May 1, 2009-April 30, 2011, goal saturation: 85%-94%; group 2, May 1, 2011-May 31, 2013, goal saturation: 88%-94%; group 3, June 1, 2013-May 31, 2015, goal saturation: 90%-95%. There was a significant reduction in the incidence of PH with higher saturation targets (86/463 [15.7%] in group 1, 30/494 [5.7%] in group 2, 28/403 [6.5%] in group 3; P < 0.001). Infants in group 2 (OR: 0.33 [95% CI: 0.21-0.51], P < 0.001) and group 3 (OR: 0.37 [95% CI: 0.24-0.59], P < 0.001) had significantly reduced odds of PH compared to infants in group 1. Use of iNO was also reduced in the higher-saturation-target groups (13/536 in group 1, 9/515 in group 2, 8/423 in group 3, P = 0.004), while bosentan and sildenafil use were not statistically different. Increasing the goal saturation range for premature infants at risk for BPD-PH is associated with reduced rates of PH diagnosis and reduced use of iNO. Era bias may have contributed to the findings. A more comprehensive analysis to account for potential confounders is underway.
Pulmonary vasodilator therapy in patients with single-ventricle physiology: effects on saturation, pressure, and progress to Fontan K Tran-Lundmark, 1,2 PK Tran, 1,2 S Moledina In children destined for single-ventricle physiology, increased PVR may halt surgical progression or result in failing Fontan. The use of pulmonary vasodilators, even at pressures of <25 mmHg, may seem reasonable. However, knowledge on indication, dosage, and effect is limited. All (n = 30) children with single-ventricle physiology treated with vasodilators by the UK Pulmonary Hypertension Service for Children in 2002-2014 were retrospectively reviewed. Mean follow-up time was 4.0 years (range: 0.5-10.9). There was no mortality and no significant ventricular dysfunction or severe AV valve regurgitation. Therapy was initiated after stage 1 (n = 11), Glenn (n = 7), or TCPC (n = 12). In stage 1 or Glenn, treatment indications were mainly increased mPAP. In TCPC, indications were PLE, ascites, plastic bronchitis, or cyanosis/reduced exercise tolerance. Average dose of phosphodiesterase inhibitor was 2.0 mg/kg/day and that of endothelin receptor antagonist (ERA) 3.4 mg/kg/day; 60% of the children received dual ther-apy. Single therapy reduced mPAP from 18.5 to 13.9 mmHg (n = 8, P = 0.004), and dual therapy from 20.2 to 14 mmHg (n = 6, P = 0.002). Five of 11 patients progressed from stage 1 to Glenn or Kawashima, and 2 of 7 from Glenn to TCPC. Primary therapy with either one or two vasodilators yielded a significant increase in saturation, from a mean of 79% to 85% (P = 0.001). Sequential addition of a second vasodilator was effective only in the Glenn group. The only severe side effect observed was a single case of reversible renal failure secondary to systemic hypotension. ERA was discontinued in 9 of 19 patients because of insufficient effect (n = 6), side effects (n = 1), or surgical progression (n = 2), and saturations remained stable. Pulmonary vasodilator therapy appears to be safe and associated with improvements in oxygenation and mPAP in children with single-ventricle physiology. It is, however, also safe to attempt weaning when no clear benefit is observed. The presence of pulmonary artery hypertension (PAH) in Fontan patients is associated with increased morbidity and mortality. Our main objective is to correlate pulmonary vascular resistance (PVR) and transpulmonary gradient (TPG) with cardiac index in Fontan patients. We suspect that patients with pulmonary artery hypertension would have lower cardiac index and worse hemodynamics. We conducted a retrospective analysis of cardiac catheterization hemodynamics of 110 Fontan patients. The median age at Fontan operation was 2.98 years, and the median age of catheterization study was 9.3 years; 31% of the patients were females, and 29% had hypoplastic left heart syndrome. The TPG (R = 0.22; P = 0.02) and PVR (R = −0.31; P = 0.0008) correlated with cardiac index. Thirty-two patients (29%) had TPG ≥ 6 (high-TPG group), while 10 patients (10%) had both TPG ≥ 6 and PVRi ≥ 3 (PAH group). The high-TPG group had a cardiac index similar to that of those with normal TPG (P = 0.13). The PAH group was found to have a lower cardiac index (P = 0.052), lower pulmonary blood flow (P = 0.03), lower pulmonary artery (PA) saturation (P = 0.036), and a lower PVR/SVR ratio (P = 0.0002), compared to the rest of the cohort. They also had a higher age at Fontan (P = 0.046). On multivariate regression analysis, the presence of PAH correlated with lower cardiac index (P = 0.006; OR: 0.32) and lower systemic artery saturation (P = 0.005; OR: 0.76). Sixteen patients (14.5%) had elevated PVR. This high-PVR group even showed significantly lower cardiac index, pulmonary blood flow, PA saturation, and aortic saturation as well as higher TPG, compared to the rest. PVR inversely correlated with cardiac index. Using PVRi ≥ 3 to define PAH will likely identify a more hemodynamically significant pulmonary vascular disease in Fontan patients. This supports the role of selective pulmonary vasodilators in improving cardiac performance in this high-risk group. Results of acute vasodilator testing (AVT) in patients with segmental pulmonary vascular disease (SPVD) have not been described. We sought to determine whether oxygen (O 2 ), O 2 with nitric oxide (NO), and diltiazem cause a similar decrease in mean pulmonary arterial pressure (MPAP) in patients with pulmonary hypertension associated with SPVD. Retrospective review of all subjects with MPAP > 25 mmHg between January 2000 and December 2015 was performed. Subjects with SPVD involving at least two major lung segments due to pulmonary venous or arterial obstruction were included. Baseline hemodynamic measurements were performed with patients breathing 21%-30% O 2 (interval 1). AVT was performed using 100% O 2 (interval 2). Selected patients were also evaluated using 100% O 2 with 20 ppm nitric oxide (O 2 with NO; interval 3), 21%-30% O 2 (interval 4), and 21%-30% FiO 2 with intravenous diltiazem at a dose of 30-60 μg/kg/min (interval 5). A t test was used to compare the change in MPAP between intervals (significant at P < 0.05). Eight of 16 patients were deemed acutely responsive during O 2 or O 2 with NO, based on a decrease in MPAP of ≥10 mmHg, to a value of <40 mmHg. Two patients were deemed acutely responsive to diltiazem. The change in MPAP with O 2 or O 2 with NO (19 ± 12 mmHg) was significantly greater than the change with diltiazem (7 ± 5 mmHg). O 2 , O 2 with NO, and diltiazem decrease MPAP in some patients with SPVD. However, the acute response to diltiazem suggests that an optimal response to therapy will not be achieved with a calcium channel blocker alone. Premature birth disrupts pulmonary vascular growth and development. The long-term consequences of altered pulmonary vasculature on pulmonary hemodynamics beyond the neonatal period are not well known. Doppler echocardiography-derived pulmonary artery acceleration time (PAAT), which inversely correlates with pulmonary artery pressure and resistance, is a reliable quantitative index of pulmonary hemodynamics. The objective of this study was to assess and compare pulmonary hemodynamics by PAAT at 1 year of age in preterm-born and term-born infants. In a prospective study of 80 preterm infants (<29 weeks gestational age at birth) enrolled through the Premature and Respiratory Outcomes Program (NCT01435187), PAAT was measured at 1 year corrected age and compared to those of 100 age-and weight-matched term-born healthy infants. PAAT was derived from pulse Doppler interrogation across the pulmonary valve in the parasternal shortaxis view and calculated as the time interval (ms) from onset of systolic pulmonary arterial flow to peak flow velocity. PAAT was adjusted for heart rate against right ventricular ejection time (RVET) using the ratio PAAT ∶ RVET. Chronic lung disease (CLD) was diagnosed in 48 infants (60%), according to the 2001 NIH workshop definition. All preterm infants had significantly lower PAAT and PAAT ∶ RVET than term-born infants at 1 year corrected age (73 ± 8 vs. 98 ± 5 ms and 0.31 ± 0.04 vs. 0.40 ± 0.02; P < 0.001). Pretermborn infants with CLD had lower PAAT and PAAT ∶ RVET than those without CLD (69 ± 5 vs. 79 ± 4 ms and 0.29 ± 0.02 vs. 0.33 ± 0.06; P < 0.01) and significantly lower values than normal-term-born infants at 1 year of age (69 ± 5 vs. 98 ± 5 ms and 0.29 ± 0.02 vs. 0.40 ± 0.02; P = 0.002). Data analysis included adjustment for gestational age at birth, sex, heart rate, and presence of significant left-to-right shunt. Preterm-born infants exhibit abnormal pulmonary hemodynamics at 1 year of age irrespective of neonatal lung disease status. This suggests persistence of pulmonary vascular dysfunction in preterm-born infants beyond infancy that warrants long-term follow-up. PAAT measurements may offer a reliable noninvasive tool for longitudinal monitoring of pulmonary hemodynamics in infants. Pulmonary veno-occlusive disease (PVOD) is a rare, severe form of pulmonary hypertension. Lung transplantation is recommended as therapy. We hypothesized that pediatric patients with PVOD might be an appropriate indication for lung transplantation. The study population consisted of 6 patients with PVOD; age range was 6.4-18.0 years. Three patients were female. Initial clinical diagnoses were asthma (4), idiopathic pulmonary arterial hypertension (1), and an asymptomatic sibling of a patient with PVOD (1). Genetic testing identified mutations in 2 siblings in the EIF2AK4 gene. One other patient had positive family history. At referral, 2 patients were receiving pharmacotherapy, and 1 had iloprost added to his regimen while in critical condition.
Six-minute walk tests in 4 patients showed distances below predicted values and hypoxemia (lowest SaO 2 range: 78%-85%). Echocardiography showed RV dysfunction in 5 patients, with moderately to severely depressed function in 3. Pulmonary vascular resistance ranged from 5 to 39 WU/m 2 (median: 20 WU/m 2 ). Pulmonary angiography in 1 patient showed capillary blush that suggesting pulmonary capillary hemangiomatosis. Chest CT scanning was distinctively abnormal, with ground-glass densities in a centrilobular distribution, mediastinal adenopathy in 3 patients, and septal lines in 5 (absent in 1). Five patients were listed for transplantation; 1 died of right ventricular failure. Four waited 3-18 days for donor organs-3 critically ill in ICU, 1 on ECMObefore bilateral lung transplantation. All survived surgery and are alive 7-50 months after surgery. Echocardiography normalized in all surviving patients. We believe that PVOD should be recognized as a distinct, potentially malignant form of PH in children. Referral for lung transplantation should be an urgent consideration. Mid-term outcomes after lung transplantation seem reasonable.
Histopathology and computed tomographic findings in a pediatric cohort with pulmonary veno-occlusive disease referred for lung transplantation Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension. Characteristic features that distinguish PVOD from idiopathic pulmonary arterial hypertension relate to histopathology and radiographic findings.
We hypothesized that a pediatric PVOD cohort might be distinctive. Six patients were referred to us for lung transplantation with a diagnosis of PVOD. Histopathology was available for 5 and chest CT scans for 6. The clinical features of the 6 patients were presented in the previous abstract. Four patients underwent lung transplantation; explant histopathology was available for review. One patient had an autopsy after death on the wait list. Patient 3 showed diffuse sickling of RBCs in the alveolar spaces. He was known to have sickle cell trait before transplantation, and, retrospectively after transplant, a diagnosis of sickle cell trait with alpha thalassemia-a benign combination according to hematology consultants-was made. CTs showed diffuse centrilobular groundglass opacities. Mediastinal adenopathy was noted in 3 patients. Septal lines were prominent in 3, mild in 2, and absent in the asymptomatic sibling. During cardiac catheterization, prominent capillary blush was noted in 1 patient. In the patient with sickle-alpha thalassemia, the CT findings showed more paucity of vascular markings and more diffuse ground-glass opacities. The histopathology and CT findings in this cohort of pediatric patients with PVOD are similar to those in an adult series. Important interindividual differences exist. CT scan alone is diagnostic. Pulmonary hypertension (PH) is difficult to recognize clinically. Simultaneous collection of heart sounds with digital stethoscopes offers an opportunity to reevaluate the auscultatory features that may lead to a diagnosis of PH. We hypothesized that the synchrony of simultaneously collected heart sounds would differ between children with PH and those without PH. We recorded heart sounds simultaneously from the 4 traditional auscultatory areas on the chest, using a digital stethoscope, in 39 subjects (20 males) with a median age of 53 years (range: 5 months-85 years) undergoing cardiac catheterization. Seventeen subjects had a mean pulmonary artery pressure (mPAp) of <25 mmHg (9-22 mmHg). Twenty-two subjects had an mPAp of ≥25 mmHg (25-56 mmHg). We applied the synchrony measures with leave-one-out cross validation to the heart sounds to examine the frequency domain through fullfrequency directed transfer function (ffDTF). The significance of the results was determined with a rank-sum test. The ffDTF increased significantly in subjects with mPAp ≥ 25 mmHg versus those with mPAp < 25 mmHg, with a P value of <0.005. The increased ffDTF suggests that the heart sounds of PH patients demonstrate greater synchronicity than those of subjects with a normal PA pressure undergoing cardiac catheterization within the optimized frequency band 13-30 Hz. This finding may provide new insights into the cardiovascular physiology of PH and alternative methods of diagnosis using heart sound recordings.
Serial N-terminal pro brain natriuretic peptide levels predicted decreased right ventricular dysfunction in children with pulmonary arterial hypertension We sought to determine whether N-terminal pro brain natriuretic peptide (NT-proBNP) measurements in children with pulmonary hypertension (PAH) predicted decreased right ventricular (RV) function. We analyzed retrospectively the health records of all children with PAH who had NT-proBNP levels measured at cardiac catheterization and on follow-up from 2008 to 2015. We recorded Panama functional class (PFC), tricuspid annular plane systolic excursion z score (TAPSE z score), RV fractional area change (RVFAC), hemodynamic data, and need for hospitalization. Hospitalization due to worsening PAH was defined as need for additional or up-titration of PAH-specific therapy or death. Fifty-three patients (median age: 46 months [range: 2-204], 30 males) were identified. At baseline, mean pressures were as follows: right atrial: 5 ± 2 mmHg; aortic: 68 ± 15 mmHg; pulmonary artery: 48 ± 20 mmHg; and wedge: 7 ± 3 mmHg. Pulmonary vascular resistance index was 12 ± 8 Wood units·m 2 .
Patients with an NT-proBNP value of >40 pmol/L were more likely to be in PFC IIIa, IIIb/IV (n = 17 vs. 4, P = 0.004) and to have a decreased TAPSE z score (mean −2.1 ± 2.09 vs. −0.5 ± 2.08, P = 0.008) and RVFAC (mean RVFAC: 27% ± 11.3% vs. 37.2% ± 6%, P = 0.0006). Hospitalization occurred in 18 patients (32%) during mean follow-up of 12 (2-98) months. Patients with PAH-related admissions (n = 9) had a median RVFAC of 21% (14%-44%) versus 33% (16%-56%), P = 0.02; a median TAPSE z score of −4.4 (−6 to 3.5) versus −1 (−1.7 to 0.2), P = 0.04; and increased NT-proBNP levels ( Respiratory syncytial virus (RSV) infection is the most frequent cause of acute lower respiratory tract disease in infants. Reports have suggested that infants with congenital heart disease (CHD), chronic lung disease (CLD), prematurity, Down syndrome, or pulmonary hypertension (PH) are associated with increased severity of RSV infection. We sought to determine the incidence of PH and assess the severity of illness associated with PH in RSVinfected infants. Echocardiograms of 155 children admitted with RSV bronchiolitis were retrospectively reviewed. Indirect measures of PH were used to categorize subjects with PH, including peak tricuspid regurgitation gradient, interventricular septal curvature geometry, early and end-pulmonary insufficiency gradient, and the left ventricle-to-right ventricle ratio in systole in short-axis view. Geographic data were collected. The association with PH and clinical outcomes, including mortality, ICU admission, prolonged ICU stay (>10 days), tracheal intubation, and need of high-frequency oscillator ventilation (HFOV), were evaluated. Echocardiography detected PH in 29 patients (18.7%). PH was observed more frequently in patients with CHD (11/33), CLD (12/25), prematurity (<38 wGA; 17/59), and Down syndrome (4/10). However, even in patients without these risk factors (n = 68), 5 patients had PH, and PH was associated with ICU admission (P = 0.003) and HFOV ventilation (P = 0.013 Our objectives were to determine prevalence and risk factors for pulmonary hypertension (PH) in preterm infants with bronchopulmonary dysplasia (BPD) by prospective echocardiographic screening and to evaluate the role of biochemical markers in screening for PH. The study was a prospective institutional echocardiographic PH screening at 36-38 weeks corrected gestational age (GA) for infants born at <32 weeks GA who were diagnosed with BPD. A subgroup of 20 infants with <750-g birth weight (BW) and/or <27 weeks GA was tested for quantitative plasma amino acids and NT-proBNP. In total, 159 infants were screened (GA: 25.9 ± 2 weeks, BW: 831 ± 286 g). The PH prevalence was 28% (44/159). BW and GA were lower in infants with PH than in those with no PH. After correction for BW and GA, necrotizing enterocolitis (NEC), severe intraventricular hemorrhage, atrial septal defect, and mortality were independently associated with PH. Screening only infants with NEC and those with BPD who had a BW of <840 g would have yielded an 86% (38/44) sensitivity for detecting PH and reduced the number of screening echocardiograms performed by 31%. In the subgroup of 20 infants who had additional biochemical screening, 25% (5/20) had evidence of PH by echocardiography. NT-proBNP levels of >1,000 pg/mL and citrulline levels of <29 μmol/L predicted PH with 100% sensitivity. In our institution, PH in preterm infants with BPD is associated with lower GA and BW, as well as NEC and severe IVH after correction for GA and BW. If these results are validated in a larger study, NT-proBNP may replace echocardiography as a PH screening tool in infants at lower risk for PH. The lower citrulline levels seen in infants with PH may have therapeutic utility in the future.
Innovative treatment for hemoptysis associated with inoperable pulmonary venous obstruction MSW Yamauchi, MH Martin, HR Muntz, RW Day Primary Children's Hospital and University of Utah, Salt Lake City, Utah, USA Inoperable pulmonary venous obstruction is a rare, though serious, medical condition leading to a significant risk of morbidity and mortality in children. Hemoptysis may occur secondary to bronchial venous congestion. Pneumonectomy has resulted in resolution of both bronchial varices and hemoptysis.
Here we report the use of a vascular plug to limit flow to a segment of lung in order to alleviate hemoptysis in a 15-year-old with Down syndrome and an occluded left lower pulmonary vein. The patient developed varying degrees of stenosis of all pulmonary veins during infancy. Surgery alleviated the stenosis of the right pulmonary veins. He had left lower pulmonary vein occlusion and a stable degree of severe left upper pulmonary vein stenosis that did not have a lasting response to balloon dilation, based on noninvasive estimates of pulmonary venous pressure. He had an elevated mean pulmonary arterial pressure despite treatment with a calcium channel blocker, a phosphodiesterase V inhibitor, and endothelin receptor antagonists. For a year, the patient had large-volume hemoptysis at least twice a month. Bronchoscopy showed dilated vessels and corrugated mucosa of the left main-stem bronchus. An 8-mm Amplatzer Vascular Plug II was placed in the left lower pulmonary artery. The patient tolerated the procedure well. Bronchoscopy 2 months after the procedure showed a marked reduction in the severity of left bron-chial vascular congestion after occlusion of the left lower pulmonary artery. Hemoptysis has not recurred over an interval of 28 months. By occluding the peripheral pulmonary arteries that supply areas of lung with inoperable venous obstruction, distal pulmonary arterial pressure and flow may decrease, bronchial varices may regress, and the frequency and severity of hemoptysis may decrease.
Single-center use of inhaled treprostinil in pediatric patients at standard and above-standard doses Inhaled treprostinil has been shown to be safe in pediatrics up to a maximum dose of 9 breaths 4 times a day (QID). We describe our use of inhaled treprostinil up to and over 9 breaths QID. Medical charts of established PH patients receiving inhaled treprostinil were reviewed. Clinical, imaging, catheterization, and lab data were analyzed. Ten patients were given inhaled treprostinil (5 with idiopathic PAH, 2 with congenital heart disease-associated disease, 2 with congenital diaphragmatic hernia, and 1 with chronic lung disease). Average age was 10 years (range: 4.8-16.1 years). Mean (median) duration of therapy was 1.7 (1.3) years (range: 0.8-4.5 years). Average WHO class at the start of therapy was 2.3, with improvement in WHO class of 0.4 by 9 breaths/dose. All patients were titrated to 9 breaths/dose. Average catheterization mean pulmonary artery pressure (MPAP) improved by 8.33 mmHg (P = 0.9), and pulmonary resistance improved by 3.42 WU*m 2 (P = 0.16). Two patients had MPAP decrease to less than 25 mmHg. Treadmill exercise testing (n = 7) by the modified Bruce protocol showed a mean improvement of 2.8 minutes (P = 0.049). Side effects were transient: cough (n = 4), nosebleeds (n = 3), dizziness, flushing, and headache (n = 1 for each). No patient withdrew for side effects. Two patients transitioned to IV therapy because of clinical worsening. Four patients were increased to 12 and one to 15 breaths QID. No change in WHO class or side effects was noted at greater than 9 breaths. Inhaled treprostinil is safe in pediatric patients showing improvement in exercise with a trend toward improvement in MPAP and can be well tolerated even at high doses, up to 15 breaths QID. Inhaled treprostinil is a good prostacyclin option in pediatric patients. The diagnosis of pulmonary hypertension (PH) is delayed or missed during the early stages of the disease because the clinical signs are difficult to discern. We sought to investigate whether speech-recognition algorithms could differentiate between the pulmonary heart sounds (P2) in subjects with PH and those in subjects without PH. Furthermore, we hypothesized that an automated, speech-recognition-inspired classification algorithm applied to heart sound recordings would outperform trained clinicians in the diagnosis of PH. Heart sounds, electrocardiograms, and pulmonary artery pressure (PAp) were recorded simultaneously. Digitized heart sound recordings were used to train and test speech-recognition-inspired classification algorithms. We extracted heart sound features with mel-frequency cepstral coefficients. We built Gaussianmixture models to classify the features as PH or non-PH. Clinicians, blinded to clinical data, listened to randomized digitized phonocardiograms. We defined PH as a mean PAp ≥ 25 mmHg. We studied 164 subjects, 86 with PH Treprostinil, a prostanoid used to treat pulmonary arterial hypertension (PAH), can be delivered by continuous intravenous (IV) or subcutaneous (SC) infusion, by inhalation, or orally (PO). There are no published reports of SC/IVto-PO transition in pediatrics, and optimal transition protocols have not been defined. Transition of patients receiving high-dose treprostinil is controversial. This series describes two individualized transition strategies. Patient 1, a 17-year-old male with advanced idiopathic PAH (IPAH) since age 2, was unwilling to continue SC infusion because of site pain. He was transitioned from 153 ng/kg/min SC to 25 mg PO TID over 10 weeks at home. Patient 2, a 19 year-old-female with IPAH since age 17, had severe local reaction to SC infusion. She was transitioned from 40 ng/kg/min to 7.5 mg PO TID in the hospital over 5 days. Both patients had pre-and posttransition studies and were monitored during transition for clinical decompensation and adverse reactions. Both patients tolerated the transition well. Both had improvement in 6-minute walk distance and no significant change in B-type natriuretic peptide, functional class, or echocardiographic parameters. Patient 1 was catheterized before and after transition and had no significant change in hemodynamics. Patient 2 was catheterized before any treatment was started and after transition to PO delivery, with dramatic hemodynamic improvement. We describe two successful but very different SC-to-PO transition strategies for patients with IPAH receiving treprostinil. This can be done safely both at home and in the hospital. Patients receiving high-dose SC therapy with advanced disease can be safely switched to oral therapy without significant deterioration in clinical status in the short term. Setting and speed of transition should be individualized to the patient. In the setting of a very high baseline treprostinil dose, a slow transition at home should be considered. Reduced wall shear stress (WSS)-associated with endothelial mechanotransduction-in the proximal pulmonary arteries in pulmonary arterial hypertension (PAH) patients has been associated with vascular stiffening. Serial, noninvasive evaluation of the relationship of WSS to vascular stiffening is still unknown. Here we aimed to retrospectively investigate time-dependent changes in maximum WSS in pediatric PAH patients who underwent successive phase-contrast MRI (PC-MRI). Twenty-one pediatric PAH patients with more than one PC-MRI visit were included. Segmented cross-sectional planes for WSS measurements were placed at the mid-level of the main pulmonary artery (MPA) and in the right pulmonary artery (RPA) 3 cm distally from the bifurcation. Vascular stiffness in each subject was assessed by relative area change (RAC: [(A max − A min )/A max ] × 100 [%]). Changes in WSS and RAC were evaluated with vector origin plots. Spearman rho was used to test correlations among changes in hemodynamic indices. The average time between serial PC-MRI acquisitions was 941 days. In the MPA, all patients with depressed maximum WSS (n = 12) presented a parallel decrease in RAC, and, conversely, all patients showing increased WSS (n = 9) showed increased RAC. Furthermore, chronological change in RAC correlated linearly with the change in maximum WSS (rho = 0.805, P < 0.001). In the RPA, 7 patients showed parallel decreases in WSS and RAC, 4 patients showed no change in RAC with concomitant decreases in WSS, and 5 patients had parallel increases in WSS and RAC. Positive significant linear correlation existed between the change in maximum WSS in the RPA and corresponding RAC (rho = 0.618, P < 0.01). Changes in maximum WSS measured in the MPA in pediatric PAH patients correspond to alterations in vascular stiffness. The noninvasive evaluation of WSS via PC-MRI may become an important follow-up modality in order to investigate the vascular pathophysiology in the progression of pediatric PAH.
Safety and outcomes of treprostinil in neonates with pulmonary hypertension
